Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study is a prospective, single-arm, single-center, phase II study. The goal of this clinical trial is to explore the therapeutic value of the treatment model of \"tislelizumab combined with chemotherapy followed by radiotherapy/adaptive surgery\" on larynx Preservation of locally advanced hypopharyngeal cancer and laryngeal cancer.
Epistemonikos ID: fdca4ca8d4e38992ec4e13e337fbcdd06c38171a
First added on: Sep 01, 2024